ArticleMolecular imaging and radionuclide therapy2021
Article in Molecular imaging and radionuclide therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Diagnostic Performance of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Correlation ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Hitting the bullseye: PSMA-targeted small molecule drug conjugate for prostate cancer treatment.RSC advances · 2026Article
- Article
- Prostate-specific membrane antigen-targeting radiopharmaceuticals: a new frontier in hepatic malignancies.Frontiers in oncology · 2025Review
- Diagnostic value ofCancer biology & therapy · 2024Article
- Review
- Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals.Diagnostics (Basel, Switzerland) · 2024Review
- Demonstration of therapy response to radioembolization withEuropean journal of nuclear medicine and molecular imaging · 2023Article
- A case of well-differentiated hepatocellular carcinoma detected withQuantitative imaging in medicine and surgery · 2023Article
- Review
- PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications.Diagnostics (Basel, Switzerland) · 2023Review
- Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment.Case reports in surgery · 2023Article
- Emerging theragnostic radionuclide applications for hepatocellular carcinoma.Frontiers in nuclear medicine · 2023Review
- Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?Journal of clinical medicine · 2022Review
- PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?Cancers · 2022Review
- Review
- Role of Peptides in Diagnostics.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to compare the metabolic parameters obtained from Methods: Fourteen patients were recruited after dynamic magnetic resonance imaging (MRI) of the upper abdomen, and Results: On visual assessment, five patients (36%) experienced low Conclusion:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.